Related Experiment Video
Updated: Jul 11, 2025
12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
7.8K
National Long-term Survival Estimates After Radical Prostatectomy for Prostate Cancer
Kristian D Stensland1, Megan E V Caram2, Daniel J Herr3
1Department of Urology, University of Michigan, Ann Arbor, MI.
Urology
|November 11, 2023
Summary
Men with recurrent prostate cancer after radical prostatectomy have improved survival rates compared to historical data. These updated survival estimates for prostate cancer recurrence and metastasis are vital for patient counseling and clinical trial design.
Area of Science:
- Urology
- Oncology
- Medical Statistics
Background:
- Radical prostatectomy is a primary treatment for localized prostate cancer.
- Understanding long-term outcomes after surgery, including recurrence and metastasis, is crucial for patient management.
- Contemporary survival data for prostate cancer patients are needed to reflect current treatment efficacy.
Purpose of the Study:
- To evaluate survival and disease control, including metastasis-related outcomes, in a large cohort of patients treated with radical prostatectomy for localized prostate cancer.
- To provide updated survival estimates for men experiencing biochemical recurrence or metastasis after prostate cancer surgery.
- To inform patient counseling and clinical trial design with current outcome data.
Main Methods:
- Retrospective analysis of 21,992 men with localized prostate cancer treated with radical prostatectomy (2005-2015) within the Veterans Health Administration.
- Biochemical recurrence (BCR) defined as prostate-specific antigen (PSA) ≥0.2 ng/mL; metastatic prostate cancer identified using a validated natural language processing dataset.
- Kaplan-Meier and cumulative incidence methods used to estimate overall survival, BCR-free survival, metastasis-free survival, and prostate cancer-specific survival.
Main Results:
- 27% of patients (5951/21,992) developed BCR; 11% of those with BCR (677/5951) developed metastases.
- Estimated 10-year cumulative incidence of BCR was 28%, and metastases after BCR was 20%.
- Median overall survival after BCR was 14 years (10-year survival 70%); median overall survival after metastasis was 7 years (10-year survival 34%). Prostate cancer-specific survival at 10 years was 94% for the entire cohort.
Conclusions:
- Men with biochemically recurrent prostate cancer following radical prostatectomy demonstrate longer survival in contemporary cohorts compared to historical data.
- Updated survival estimates for recurrent and metastatic prostate cancer are essential for accurate patient counseling.
- These findings provide valuable benchmarks for designing future clinical studies and managing patients post-prostatectomy.
More Related Videos
Related Concept Videos
01:21Cancer Survival Analysis
357
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
357
01:20Actuarial Approach
80
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
80
01:24Kaplan-Meier Approach
154
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
154
01:20Comparing the Survival Analysis of Two or More Groups
200
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
200